Kodiak Sciences Inc.
NASDAQ:KOD · NASDAQ Global Market
-$0.03 today
Vol 1.21M · Avg 1.10M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:KOD · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$230.7M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-4.17, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 -100.0% | $26.7M +2.9% | $25.9M +135.9% | $11.0M +26.3% | $8.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 +100.0% | -$26.7M -2.9% | -$25.9M -135.9% | -$11.0M -26.3% | -$8.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $182.4M +44.6% | $126.1M -38.9% | $206.3M -22.9% | $267.6M +23.1% | $217.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $52.0M +52.8% | $34.0M -52.1% | $71.0M +13.1% | $62.8M +53.1% | $41.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $234.4M +46.4% | $160.1M -36.3% | $251.4M -23.9% | $330.4M +27.9% | $258.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $26.3M -1.4% | $26.7M +2.9% | $25.9M +135.9% | $11.0M +26.3% | $8.7M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$203.6M -36.2% | -$149.5M +36.3% | -$234.5M +27.3% | -$322.8M -25.0% | -$258.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$234.4M -25.4% | -$186.8M +32.6% | -$277.3M +18.8% | -$341.4M -27.8% | -$267.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $4.5M -59.5% | $11.1M -33.4% | $16.7M +136.6% | $7.1M +2272.8% | $298.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 -100.0% | $13.0K -27.8% | $18.0K -18.2% | $22.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $4.4M -58.5% | $10.6M -36.8% | $16.8M +122.7% | $7.6M +12286.9% | $61.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$230.0M -30.5% | -$176.2M +32.4% | -$260.5M +22.0% | -$333.8M -25.0% | -$267.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$230.0M -30.5% | -$176.2M +32.4% | -$260.5M +22.0% | -$333.8M -25.0% | -$267.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$4 -29.0% | -$3 +32.6% | -$5 +22.2% | -$6 -23.8% | -$5 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$4 -29.0% | -$3 +32.6% | -$5 +22.2% | -$6 -23.8% | -$5 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $53.2M +1.2% | $52.6M +0.3% | $52.4M +0.3% | $52.2M +0.9% | $51.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $53.2M +1.2% | $52.6M +0.3% | $52.4M +0.3% | $52.2M +0.9% | $51.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector

Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B

AnaptysBio, Inc.
NASDAQ:ANAB
$2.39B

UroGen Pharma Ltd.
NASDAQ:URGN
$1.59B

Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.49B

EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.13B

Xencor, Inc.
NASDAQ:XNCR
$928.99M

Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$856.01M

Oculis Holding AG
NASDAQ:OCS
$636.87M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$610.02M

ProKidney Corp.
NASDAQ:PROK
$263.28M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does KOD generate?
Kodiak Sciences Inc. (KOD) reported $0.00 of revenue in fiscal 2025.
Is KOD profitable?
Kodiak Sciences Inc. (KOD) reported -$229,967,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.